Search

A review of 157 consecutive biopsies of donor endomyocardium in patients with heterotopic heart transplants is reported. The technique of percutaneous transvenous endomyocardial biopsy after this operation is described; manipulation of the catheter and bioptome into the junction of the donor superior vena cava and right atrium can be difficult when this anastomotic junction is small, as a result either of operative surgical technique or of subsequent contraction. The complication rate was 4%, but one patient may have died from infection resulting from biopsy when the bioptome had to be introduced at the groin. The histopathological changes seen in the biopsy specimens have been graded according to a scoring system to give the clinician a guide to the severity of rejection. Histopathological assessment was of clinical value in 96% of cases, but was inaccurate on two occasions, once because an opinion was given on what was in retrospect an inadequate sample. In patients undergoing persistent low-grade acute or chronic rejection there was difficulty in detecting or appreciating the true extent of myocardial fibrosis; this led to inadequate immunosuppressive treatment in two patients. Attention is drawn to the fact that ischaemic fibrosis resulting from the vascular changes of chronic rejection may spare the endomyocardium, which is kept viable by intracavitary blood, and that this may lead to a misleading histopathological report. [ABSTRACT FROM AUTHOR]

The results of the morphologic and histopathologic examination of 37 bovine pericardial heart valve prostheses that were retrieved after experimental implantation in Chacma baboons for periods of one to twelve months are presented in this study. The implanted prostheses consisted of 33 Mitroflow valves, size 21 mm, that belonged to four different groups according to the method of preparation of the pericardium (process I to IV) and 4 commercially available Ionescu-Shiley valves, size 19 mm. All implantations were in the mitral position, except 1 Mitroflow and 1 Ionescu-Shiley prosthesis, which were implanted in the tricuspid position. Moderate or abundant noninfected thrombotic deposits were found on the cusps of 13 of the 33 Mitroflow valves (39%). The Ionescu-Shiley valves shared this tendency, perhaps to a lesser extent, for the formation of thrombus on the valve cusps. Results of transmission electron microscopy, scanning electron microscopy, and calcification analysis are also presented. In this experimental study, the authors did not identify any significant characteristics in the Mitroflow bovine pericardial heart valve prosthesis that would lead to improved or extended durability of this device over the commercially available Ionescu-Shiley bovine pericardial heart valve prosthesis and probably over any other glutaraldehyde-treated bioprosthesis. They would suggest, therefore, that any clinical investigations of the prosthesis be undertaken very cautiously. [ABSTRACT FROM AUTHOR]

Evaluation of possible enhanced durability of the Mitroflow pericardial heart valve prosthesis was undertaken in an experimental animal model using the Chacma baboon. For comparison purposes a small series of 4 Ionescu-Shiley pericardial valves were also implanted. The 33 Mitroflow prostheses implanted were all manufacturer's size 21mm and belonged to 4 different groups according to the process used for the preparation of the pericardium (Process I to IV). The Ionescu-Shiley prostheses were all manufacturer's size 19mm and were commercially available valves. The valves were implanted in the mitral position, except one each Mitroflow and Ionescu-Shiley prosthesis that was implanted in the tricuspid position. Four animals died in the early postoperative period, between 2 and 14 days. Two died from a probable viral infection, one from a low cardiac output state and the fourth one from bacterial endocarditis. The clinical evaluation of the animals for an implantation time of up to twelve months was unremarkable. Hemodynamic studies were performed immediately after implantation (n=29), at an intermediate cardiac catheterization at 9 months after implantation (n=4) and at the time of terminal elective sacrifice of the animals (n=33). From the data obtained the resultant prosthetic valve area at the time of elective sacrifice of the animals was also calculated. The data obtained for each of the 5 groups of valves tested are presented in the text. Transvalvular gradients measured at the time of sacrifice of the animals were elevated. Statistically however the rate of change of pressure gradient per month did not differ significantly from the controls (Ionescu-Shiley valves) for each of the processes I to IV. As far as it could be ascertained in this study the Mitroflow size 21mm bovine pericardial heart valve prosthesis, although it went through multiple modifications during the study period, did not prove to have any significant long-term hemodynamic advantage over the Ionescu-Shiley size 19 mm bovine pericardial heart valve prosthesis. [ABSTRACT FROM AUTHOR]

Heart failure can be treated with devices that mechanically support the circulation. The improvement of these devices would benefit many patients, especially those refractory to maximal pharmacological treatment and ineligible for heart transplantation. This study examined whether the shape memory alloy (SMA) fibers, which are fibers that contract when electric current flows through them and relax passively when that flow is interrupted, can be wrapped around the failing heart and assist in its pumping action. A band of SMA fibers was wrapped around a silicon cylindrical chamber which simulated a dilated heart and its pumping action was tested in a circulatory mockup. This rudimentary device was innovatively controlled by pulse width modulation. The band was made of only six fibers but yet produced the considerable pressure of 20 mm Hg and a stroke volume of 11.8 ml with modest energy demands. A SMA device could assist a severely failing heart, but there are limiting factors to overcome before designing highly effective devices.

Several studies have reported an association between infectious agents and atherosclerosis. Cytomegalovirus (CMV) is the most commonly implicated viral pathogen. However, the role of CMV in atherosclerosis remains obscure. The present study evaluated the presence of CMV DNA in atherosclerotic plaques and normal vessel walls. A total of 40 arterial specimens from coronary plaques and 27 samples from normal vessels were obtained from 26 patients who underwent aortocoronary bypass surgery. The specimens were analyzed by polymerase chain reaction for the presence of the CMV immediate early genomic region. CMV DNA was detected in 9 out of 26 patients (34.6%). Viral DNA was detected in both nonatherosclerotic tissues and atherosclerotic plaques. No statistically significant differences were observed between normal and diseased vessels. Our findings, in accordance with previous studies, do not support a direct causative role of CMV in the development of atherosclerotic plaques.

We present a 76-year-old woman with infective endocarditis of a prosthetic aortic valve. The course of her illness started with an ischaemic stroke and she was admitted with prolonged fever and an episode of loss of consciousness. Echocardiography revealed acute aortic regurgitation and dehiscence of the prosthetic valve with excessive "rocking motion", aortic abscesses and left ventricular outflow obstruction caused by a semilunar shelf of tissue probably due to endocarditis vegetations. She underwent an urgent surgical procedure that confirmed the echocardiographic findings. Our case report reinforces the value of early diagnosis in the presence of a high clinical suspicion of prosthetic valve endocarditis. An extended workup, including transoesophageal echocardiography, in such a patient with a mechanical valve is mandatory.

Christiaan (Chris) Barnard was born in 1922 and qualified in medicine at the University of Cape Town in 1946. Following surgical training in South Africa and the USA, Barnard established a successful open-heart surgery programme at Groote Schuur Hospital and the University of Cape Town in 1958. In 1967, he led the team that performed the world's first human-to-human heart transplant. The article describing this remarkable achievement was published in the South African Medical Journal just three weeks after the event and is one of the most cited articles in the cardiovascular field. In the lay media as well, this first transplant remains the most publicised event in world medical history. Although the first heart transplant patient survived only 18 days, four of Groote Schuur Hospital's first 10 patients survived for more than one year, two living for 13 and 23 years, respectively. This relative success amid many failures worldwide did much to generate guarded optimism that heart transplantation would eventually become a viable therapeutic option. This first heart transplant and subsequent ongoing research in cardiac transplantation at the University of Cape Town and in a few other dedicated centres over the subsequent 15 years laid the foundation for heart transplantation to become a well-established form of therapy for end-stage cardiac disease. During this period from 1968 to 1983, Chris Barnard and his team continued to make major contributions to organ transplantation, notably the development of the heterotopic ( 'piggy-back') heart transplants; advancing the concept of brain death, organ donation and other related ethical issues; better preservation and protection of the donor heart (including hypothermic perfusion storage of the heart; studies on the haemodynamic and metabolic effects of brain death; and even early attempts at xenotransplantation.

We describe the case of a 53-year-old man with a severely stenotic bicuspid aortic valve combined with an unruptured aneurysm of the left sinus of Valsalva and an aberrant left coronary artery. The patient was successfully treated with aortic valve replacement and closure of the aneurysm. It is well known that patients with a bicuspid aortic valve have an increased incidence of other congenital anomalies, but the combination presented in our case is very rare.

Introduction: Levosimendan is a new inotropic vasodilator for the treatment of decompensated heart failure. Compared to other inotropic agents, it has been shown to improve myocardial contractility without increasing oxygen requirements. However, experience with levosimendan in patients with low cardiac output after cardiopulmonary bypass is limited. In this case series we present the short-term haemodynamic effects of levosimendan added to dobutamine for the management of low cardiac output syndrome after cardiac surgery., Methods: Twelve patients with low cardiac output during the first 6 hours after completion of cardiopulmonary bypass, who were already receiving dobutamine at a mean dose of 6.7 microg/kg/min, were treated with levosimendan at a loading dose of 6 microg/kg, followed by a 24-hour infusion of 0.2 microg/kg/min. During a 24-hour observation period the following haemodynamic parameters were measured: arterial, central venous, pulmonary arterial and pulmonary capillary wedge pressure, heart rate, cardiac index, stroke volume, systemic and pulmonary vascular resistance, as well as mixed venous oxygen saturation, oxygen delivery and oxygen extraction ratio., Results: Levosimendan significantly improved cardiac index (from 2.1 +/- 0.1 L/min/m2 at baseline to 3.2 +/- 0.3 L/min/m2 at 24 hrs, p < 0.001) as well as mixed venous oxygen saturation, oxygen delivery and oxygen extraction ratio (p < 0.001) and caused a significant reduction in systemic and pulmonary vascular resistance (p < 0.001). At the same time, a significant decrease in central venous, pulmonary arterial and pulmonary capillary wedge pressure was noted (p < 0.001). These beneficial haemodynamic effects resulted in significantly decreased catecholamine requirements., Conclusions: In this group of cardiac surgical patients with postoperative myocardial dysfunction resistant to dobutamine, levosimendan added to dobutamine was effective in reversing low cardiac output syndrome.

Ten patients, all men, have been operated of heterotopic heart transplantation since the end of 1974. Ages ranged from 59 to 24 years with an average of 38 years. Six of them suffered from ischaemic heart disease, two from cardiomiopathy and two from rheumatic heart disease. All of them presented end stage cardiac disease. The first two patients underwent to left ventricular bypass only, in the remaining eight a right and left bypass was performed. At the present time, June 1977, 6 of the original 10 patients are alive all of them in functional class I. Five of them have resumed a full time job, the sixth will be soon able to do so. Four patients died. There were no deaths from acute rejection, but three died from infection, and the fourth one from a pulmonary embolus, 4 months after transplantation. There has been only one episode of acute rejection which has responded well to the treatment. The advantages of the heterotopic versus the orthotopic cardiac transplantation are discussed.

The presentation, diagnosis and management of a 13-month-old child with a left atrial myxoma is described. The value of echocardiography in confirming the diagnosis is emphasized.

The Fontan procedure was applied to correct 13 cases of tricuspid atresia, all with concordant arterial connections. Seven of the patients had had a total of ten previous operations to create palliative shunts. There were 3 early deaths, all due to low cardiac output states, but no late deaths. The postoperative management of the survivors was not unduly complicated, except in the 1st patient. Complete heart block developed transiently in 2 patients. The results are classified as good to very good in all 10 survivors. Our experience supports the opinion that the Fontan procedure gives good symptomatic relief in patients with tricuspid atresia. We discuss the possibility of improving long-term left ventricular function by early complete correction.

The performance of the St. Jude prosthetic valve is reviewed in 81 patients aged 3 to 15 years. All 66 mitral (2 re-replacements), 8 aortic and 9 double valve replacements between February 1979 and August 1984 are included. The early mortality was 3.7% and actuarial analysis shows a 90% event free survival up to 5 years. Anticoagulant therapy was used in most patients, but comparison between groups receiving warfarin or aspirin or no therapy reveals no differences in the complication rate. The valve is well suited for use in children since the early degeneration seen with heterograft valves does not occur, and anticoagulation is not essential.

Between 1 August 1975 and 31 October 1982, 76 patients aged between 70 and 82 years (mean 73,4 years) underwent elective (71) or emergency (5) valve replacements. Fifty patients underwent aortic valve replacement (including 5 with additional coronary artery bypass grafts), 19 mitral valve replacement including 3 with coronary artery bypass grafts, and 7 double valve replacements. There were 3 early deaths (3,9%) and 9 late deaths (11,8%) during the follow-up periods of 1 month - 86 months (mean 29 months). Actuarial analysis showed a survival rate of 95% at 1 year, 89% at 2 years, and 77% at 5 years. The clinical result of operation was judged to be good or excellent in all patients except one. It is concluded that valve replacement in patients over 70 years carries a low operative risk, statistically similar to that for younger patients at our institution, and is accompanied by a satisfactory result.

Between November 1974 and February 1982 40 patients underwent heterotopic heart transplantation at Groote Schuur Hospital, Cape Town. In 4 of these patients retransplantation was carried out, bringing the total number of heterotopic heart transplant operations to 44. Fourteen patients are alive to date, from 4 months to more than 7 years after transplantation. The 1-year survival rate has been 60%. Three of the first 6 patients in this series have survived for 6 years or more, while 6 of the 7 patients who received transplants during 1981 (including 2 who underwent retransplantation) are alive. Retransplantation of the donor heart, donor heart procurement from distant sources using prolonged myocardial preservation techniques and the reasons why heterotopic cardiac transplantation is more advantageous than other methods are discussed. The surgical technique and some modifications introduced since this method was first described in 1975 are presented in detail.

This is a review of the results of surgical treatment of congenital heart disease in children aged less than 12 years over the period 1975 - 1981 (1254 cases). The patients are divided into two groups, those treated between 1975 and 1979 (903 cases) and those treated in 1980 and 1981 (351 cases). Only 19,7% of the patients in the first group were under the age of 1 year, but 26,5% in the second group were in this age group. This reflects a change in policy and an attempt at surgical correction at a much younger age than was previously the case. Our present policy in cardiac emergencies in infants will be discussed. Despite the higher percentage of infants aged under 1 year who were treated in 1980 - 1981, the mortality rate was lower than that for the period 1975 - 1979. This probably reflects greater experience in the post-operative management of patients under the age of 1 year.